A part of Watch Media

Tuesday28 March 2023

29/12/2021at 07:54

Pharma & biotech

Novo Nordisk predicts period of "different" growth when semaglutide patents expire

The pharmaceutical company's growth profile will change when patents concerning the GLP-1 molecule semaglutide run out, says CEO at Novo Nordisk Lars Fruergaard Jørgensen.

Photo: Stine Bidstrup/ERH

by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

When patents related to Novo Nordisk's bestselling GLP-1 molecule, semaglutide, expire, it might affect the company's growth, CEO at Novo Nordisk Lars Fruergaard Jørgensen tells Danish business daily Børsen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Related articles:

High growth at low margins is better than the reverse, says Novo Nordisk CEO
For subscribers
Novo CEO is on the hunt for future growth: "The pressure is bigger than ever"
For subscribers
Year-to-date obesity drug sales at Novo Nordisk surpass all of 2020
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Antibiotic Dicillin has infected Danish and Icelandic patients Antibiotikummet Dicillin har smittet både danskere og islændinge med multiresistente bakterier, som patienterne sandsynligvis skal leve med resten af livet. | Photo: Lægemiddelstyrelsen / Pr

Pharma & biotech

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Sandoz ends its collaboration with the secret CMO that made the contaminated antibiotic product and cannot rule out other drugs could be infected with multi-resistant bacteria.

For subscribers

Foto: Zealand Pharma / Pr

Pharma & biotech

Zealand Pharma presents positive early-stage results for weight-loss candidate

For subscribers

Foto: Tuala Hjarnø / Genmab / Pr

Pharma & biotech

Genmab promotes senior VP for strategy to executive management

For subscribers

Foto: Ambu/pr

Ambu wins European approval of two fifth-generation bronchoscopes

For subscribers

Både danskere og islændinge har nu multiresistente bakterier i kroppen efter at have spist antibiotikummet Dicillin. | Foto: Lægemiddelstyrelsen / Pr

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

For subscribers

Foto: Novo Nordisk / Pr

Pharma & biotech

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

For subscribers

Further reading

Photo: Ida Marie Odgaard/Ritzau Scanpix

Pharma & biotech

Obesity drug hit makes Novo Nordisk more valuable than Nestle

The Danish drugmaker has climbed from seventh to second place of Europe’s most valuable firms in just two years.

For subscribers

Foto: Novo Nordisk / Pr

Pharma & biotech

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

The study tested 25mg and 50mg doses, and both showed a higher efficacy after 52 weeks compared to 14mg.

For subscribers

Foto: Tidsvilde Stine/Ritzau Scanpix

Pharma & biotech

Novo Nordisk enters collaboration with AI-driven drug discovery company

Insilico Medicine has developed an AI-driven platform that will help the Danish drugmaker identify targets against liver fibrosis.

For subscribers